Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T38078 |
TLR7/8-IN-1
TLR7/8-IN-1 |
TLR | Immunology/Inflammation |
TLR7/8-IN-1, a crystalline TLR7/TLR8 inhibitor, is a valuable compound for autoimmune disease research[1]. | |||
T39669 |
TLR7/8/9-IN-1
TLR7/8/9-IN-1 |
TLR | Immunology/Inflammation |
TLR7/8/9-IN-1 是具有口服活性的Toll 样受体7/8/9小分子拮抗剂,IC50为43 nM。 | |||
T5561 |
TLR7/8 agonist 1 dihydrochloride
TLR7/8 agonist-5d,二盐酸TLR7/8 agonist 1 |
TLR | Immunology/Inflammation |
TLR7/8 agonist 1 dihydrochloride (TLR7/8 agonist-5d) 是 toll 样受体TLR7/TLR8的双重激动剂。 | |||
T13167 |
TLR7/8 agonist 3
|
TLR | Immunology/Inflammation |
TLR7/8 agonist 3 是TLR7/8激动剂。 | |||
T72035 | TLR7/8/9 antagonist 2 | TLR | Immunology/Inflammation |
TLR7/8/9 antagonist 2 是一种具有口服活性和较高生物利用度的 vTLR7/8/9 拮抗剂。TLR7/8/9 antagonist 2 对 HEK/hTLR7、HEK/hTLR8 和 HEK/hTLR9 具有抑制作用,IC50 分别为 0.011 μM、0.029 μM 和 0,052 μM。TLR7/8/9 antagonist 2 可用于研究系统性红斑狼疮或狼疮性肾炎等自身炎症性疾病。 | |||
T39969 | TLR7/8 agonist 4 TFA | ||
TLR7/8 agonist 4 TFA (compound 41) is a highly potent TLR7/8 agonist that exhibits significant anti-cancer activity. | |||
T39968 |
TLR7/8 agonist 4 hydroxy-PEG10-acid
TLR7/8 agonist 4 hydroxy-PEG10-acid |
||
TLR7/8 agonist 4 hydroxy-PEG10-acid (compound 9) is a drug-linker conjugate employed in antibody-drug conjugates (ADC). This compound exhibits remarkable antitumor activity by utilizing TLR7/8 agonist 4, which acts as a potent activator of TLR7/8. The TLR7/8 agonist 4 is linked to hydroxy-PEG10-acid, the ADC linker, via a cleavable bond. Overall, it demonstrates promising pharmaceutical potential in the context of ADC-based therapeutics. | |||
T39970 |
TLR7/8 agonist 4 hydroxy-PEG10-acid hydrochloride
TLR7/8 agonist 4 hydroxy-PEG10-acid hydrochloride |
||
TLR7/8 agonist 4 hydroxy-PEG10-acid hydrochloride (compound 9) is a drug-linker conjugate used in antibody-drug conjugates (ADCs) with high efficacy against tumors. It consists of TLR7/8 agonist 4, a potent TLR7/8 agonist, linked to the ADC linker hydroxy-PEG10-acid which can be cleaved. | |||
T9570 |
Enpatoran
|
TLR | Immunology/Inflammation |
Enpatoran (M5049) 是一种口服有效的TLR7/8选择性抑制剂,在HEK293 细胞中,IC50s 分别为 11.1 nM 和 24.1 nM。Enpatoran 可以阻断分子合成配体和天然内源性 RNA 配体。Enpatoran 在体内具有良好的药代动力学特性。Enpatoran 在先天性和适应性自身免疫阻断方面有研究的价值。 | |||
T71108 |
TLR7/8 agonist 1
|
||
TLR7/8 agonist 1是一种 toll 样受体 (TLR7)/TLR8的双重激动剂。 | |||
T79068 | TLR7/8 agonist 8 | ||
TLR7/8 agonist 8(compound 24m)是一种高效的TLR7/8双重激动剂,对hTLR7和hTLR8的EC50值分别为27 nM和12 nM。该化合物能增强PD-1/PD-L1阻断剂的抗癌效果。 | |||
T62177 | TLR7/8 agonist 6 | ||
TLR7/8 agonist 6 (Compound 4) 是一种咪唑喹啉衍生物,是一种有效的 TLR7/8 激动剂,对 TLR7 和 TLR8 的 IC50 值分别为 0.18 和 5.34 μM。其中 Toll 样受体 (TLR) 7 和 8 是一种治疗传染病、癌症和自身免疫性疾病的免疫调节药物开发的关键靶点。 | |||
T61601 | TLR7/8 antagonist 2 | ||
TLR7/8 antagonist 2 (Compound 15) is a highly potent and orally active agonist of TLR7/8, exhibiting IC50 values of 4.9 and 0.6 nM for TLR7 and TLR8, respectively. Its strong affinity for these receptors makes it a promising candidate for the treatment and investigation of autoimmune diseases, including lupus erythematosus, which is associated with inappropriate activation of TLR7 and TLR8. Consequently, TLR7/8 antagonist 2 represents a valuable tool for research in the field of autoimmune disea... | |||
T62178 | TLR7/8 antagonist 1 | ||
TLR7/8 Antagonist 1 (Compound 16c) 是一种咪唑喹啉衍生物,是一种有效的 TLR7/8 激动剂,对 TLR7 和 TLR8 的 IC50 值分别为 3.91 和 2.19 μM。其中 Toll 样受体 (TLR) 7 和 8 是一种治疗传染病、癌症和自身免疫性疾病的免疫调节药物开发的关键靶点。 | |||
T60894 |
TLR7/8 agonist 4
|
||
TLR7/8 agonist 4 (compound 41) 是具有抗癌活性的,TLR7/8 的有效激动剂。 | |||
T79069 | TLR7/8 agonist 9 | ||
TLR7/8 agonist 9 (Compound 25a) 是一种能够增强PD-1/PD-L1阻断疗法抗肿瘤效果的化合物,主要用于癌症免疫疗法研究。它对hTLR7和hTLR8的EC50分别为40 nM和23 nM,显示出其对这两种受体的高亲和力以及潜在的抗肿瘤活性。 | |||
T72684 | TLR7/8 agonist 7 | ||
TLR7/8 agonist 7 是一种 TLR7/8激动剂。TLR7/8 agonist 7 可激活多种免疫细胞,可用于合成抗体-免疫刺激偶联物 ISAC 分子。TLR7/8 agonist 7 可用于免疫的研究。 | |||
T64606 | TLR7/8 agonist-7d | ||
TLR7/8 agonist-7d 是一种有用的有机化合物,可用于生命科学领域的相关研究,其产品编号为 T64606。 | |||
T80976 | TLR7/8 agonist 4 hydroxy-PEG6-acid | ||
TLR7/8 agonist 4hydroxy-PEG6-acid 为ADC药物-连接子偶联物(Drug-Linker Conjugates for ADC)。该合成物结合了TLR7/8 agonist 4与连接子hydroxy-PEG6-acid,专门用于ADC合成。 | |||
T77890 |
TLR7/8 agonist 4 hydroxy-PEG6-acid hydrochloride
|
||
TLR7/8 agonist 4hydroxy-PEG6-acid hydrochloride为一种用于抗体药物偶联体(ADC)的药物-连接子偶联物。该化合物为TLR7/8 agonist 4hydroxy-PEG6-acid的盐酸盐形式,由TLR7/8 agonist 4与连接子 Hydroxy-PEG6-acid构成,适用于ADC合成。 | |||
T15371 |
Gardiquimod
|
TLR; HIV Protease | Immunology/Inflammation; Microbiology/Virology; Proteases/Proteasome |
Gardiquimod 可抑制巨噬细胞和活化的外周血单个核细胞的HIV-1感染。 它是一种咪唑喹啉类似物,是一种 TLR7/8 激动剂。 | |||
T6898 |
Motolimod
VTX-378,VTX-2337 |
TLR | Immunology/Inflammation |
Motolimod (VTX-378) 是一种有效且特异性的 Toll 样受体 8 (TLR8) 激动剂,EC50约为 100 nM。 | |||
T17032 |
Telratolimod
MEDI9197,3M-052 |
TLR | Immunology/Inflammation |
Telratolimod (MEDI9197) 是TLR7/8的激动剂,具有抗肿瘤活性。 | |||
T6964 |
Resiquimod
R848,雷西莫特,S28463 |
HCV Protease; TLR | Immunology/Inflammation; Microbiology/Virology; Proteases/Proteasome |
Resiquimod (R848) 是一种 Toll 样受体7/8的激动剂,可诱导细胞因子上调。 | |||
T13182 | Toll-like receptor modulator | TLR | Immunology/Inflammation |
Toll-like receptor modulator is a TLR7/8 modulator, which modulates immune function. | |||
TNU1309 |
TLR7 agonist 10
|
||
Nucleoside Derivatives - Xylo-nucleosides, N-Methylated alkylated nucleosides; 8-Modified purine nucleosides | |||
T5499 |
gardiquimod TFA salt
|
||
Gardiquimod diTFA,咪唑啉类似物TLR7/8激动剂,可特异性抑制巨噬细胞和活化外周血单个核细胞(PBMCs)的HIV-1感染。在浓度低于10 μM时,该化合物特异性激活TLR7。 | |||
T74348 | HE-S2 | PD-1/PD-L1 | Apoptosis; Cell Cycle/Checkpoint; Immunology/Inflammation |
HE-S2是一种具有显著抗肿瘤活性的抗体偶联活性分子,它通过阻断PD-1/PD-L1相互作用并激活Toll样受体7/8 (TLR7/8)信号通路,触发有效的抗肿瘤免疫反应。 | |||
T14035 |
3M-011
|
TLR | Immunology/Inflammation |
3M-011, a potent dual toll-like receptor TLR7/8 agonist and cytokine inducer, serves as a powerful adjuvant to radiotherapy, eliciting significant local and systemic immune responses. Additionally, it effectively inhibits H3N2 influenza viral replication in the nasal cavity and exhibits strong antitumor activity[1][2][3]. | |||
T37287 |
Enpatoran hydrochloride
|
||
Enpatoran (M5049) hydrochloride is a potent and orally active dual inhibitor of TLR7/8 with IC50 values of 11.1 nM and 24.1 nM in HEK293 cells, respectively. This compound specifically inhibits TLR7 and TLR8, while showing no activity against TLR3, TLR4, and TLR9. Enpatoran hydrochloride has the ability to block both synthetic molecule ligands and natural endogenous RNA ligands. Additionally, it demonstrates excellent pharmacokinetic properties in vivo. Enpatoran hydrochloride can be a valuable ... | |||
T61390 |
D18
|
||
D18 is an immune modulator that acts as a dual agonist for TLR7/8 (with EC50 values of 24 nM for hTLR7 and 10 nM for hTLR8, respectively). It enhances the expression of PD-L1 through epigenetic regulation, thereby increasing the sensitivity of tumors to PD-1/PD-L1 blockade. Additionally, D18 functions as a cytotoxin for ADC synthesis, specifically for the ADC HE-S2 [1]. | |||
T83895 |
NCI 126224
NSC 126224 |
||
NCI 126224 是一种 toll-like receptor 4 (TLR4) 的拮抗剂。它在 RAW 264.7 巨噬细胞中,选择性抑制由 TLR4 激动剂 LPS 引起的一氧化氮 (NO) 产生(IC50 = 0.31 µM),而对 TLR7/8 激动剂 R-848、TLR1/2 激动剂 Pam3CSK4 以及 TLR3 激动剂 poly(I:C) 的影响较小;但对于相同细胞中由 TLR2/6 激动剂 FSL-1 引起的 NO 产生,其抑制作用在 0.6 µM 时亦显现。此外,NCI 126224 在 BV-2 微胶质细胞的报告实验中抑制了 LPS 引起的 NF-κB 活性,并在 RAW 264.7 巨噬细胞中降低了 LPS 引起的 IL-1β 和 TNF-α 水平(IC50s = 5.92, 0.42, 和 1.54 µM,分别)。 |